Currently Viewing:
The International Society for Pharmacoeconomics and Outcomes Research
Value Assessment Frameworks Should Represent a Spectrum of Patient Preferences
September 08, 2017
Dr Patricia Danzon: Learning From European Health Systems
August 30, 2017
Dr Ilene Hollin: One-Size-Fits-All to Value Doesn't Work
August 23, 2017
Currently Reading
Dr Patricia Danzon Highlights European Examples of Restraining Drug Prices
August 16, 2017
Dr Patricia Danzon: Cost Effective Doesn't Mean Affordable
August 03, 2017
Dr Michael Sherman on Performance-Based Risk-Sharing Agreements
July 28, 2017
Dr David Cutler Assesses the Political Odds of Drug Pricing Reform
July 25, 2017
Dr Steve Pearson on Using Health Technology Assessment to Guide Decision Making
July 23, 2017
Dr Gail Wilensky: Increased Competition a Better Drug Pricing Solution Than Cost Controls
July 16, 2017
Dr Steve Pearson on Data Needed to Evaluate Clinical and Economic Effects of New Therapies
July 14, 2017
Dr David Cutler: Trump Administration's Attention Not on Value-Based Purchasing
July 09, 2017
Dr Gail Wilensky on the Likelihood of Continuing Value-Based Reimbursement Demonstrations
July 06, 2017
Dr Steve Pearson: Patient Perspectives Guide ICER Value Framework Development
July 04, 2017
Dr Scott Ramsey Addresses the Need for Differential Pricing Structures for Drugs
July 02, 2017
Dr Gail Wilensky Raises Questions About Medicaid's Matching Grant Structure
June 25, 2017
Dr Steve Pearson Explains How ICER Price Benchmarks Align Cost With Patient Benefits
June 22, 2017
Dr David Cutler Discusses Opportunities for Bipartisan ACA Reform
June 20, 2017
Dr Scott Ramsey on Challenges of Determining Cost Effectiveness of Novel Cancer Treatments
June 19, 2017
Dr Steve Pearson's Outlook on the Ongoing Updates to ICER's Value Framework
June 18, 2017

Dr Patricia Danzon Highlights European Examples of Restraining Drug Prices

A combination of different countries’ health systems can set an example for the United States to follow in efforts to restrain the ongoing increases in drug prices, explains Patricia Danzon, PhD, the Celia Moh Professor at The Wharton School, University of Pennsylvania.


A combination of different countries’ health systems can set an example for the United States to follow in efforts to restrain the ongoing increases in drug prices, explains Patricia Danzon, PhD, the Celia Moh Professor at The Wharton School, University of Pennsylvania.

Transcript (slightly modified)

What are some example of countries that have successfully curbed drug prices that the US might want to consider? And would they even work in the US?

I would say that I think the combination of the systems. The structure of the systems in Germany and the United Kingdom but very much adapted for the US model would be an approach that I think could work here. The idea of letting the drug on the market while an assessment is being made, but then let the payers have a notion of what is the value threshold in terms of a cost per quality-adjusted life year, or some other measure of health gain, that is what they are willing to pay for a drug. Because we have a pluralistic system of payers in the United States, it wouldn’t necessarily be the same threshold for every payer.

Already we have a system where Medicare pays one price, Medicaid gets rebates, the Department of Veterans Affairs gets other rebates, and the private sector negotiates its own discounts. So, the different payers could have their different thresholds and be negotiating discounts in return for preferred formulary placement, just as they do right now. But, the whole system could be geared to something that is based off an assessed value so the prices really are based on something that is a measure of actual value delivered in terms of the patient-centric health benefits and the cost saved to the healthcare system. Whereas, at the moment the price is pretty much whatever the manufacturer chooses to name, and that contributes to our unending upward spiral of prices.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!